Check-Cap (NASDAQ: CHEK) and Repligen Corporation (NASDAQ:RGEN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitabiliy and valuation.

Volatility & Risk

Check-Cap has a beta of -0.36, indicating that its stock price is 136% less volatile than the S&P 500. Comparatively, Repligen Corporation has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Earnings & Valuation

This table compares Check-Cap and Repligen Corporation’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Check-Cap N/A N/A -$8.79 million ($0.57) -3.26
Repligen Corporation $110.04 million 12.16 $27.41 million $0.38 103.32

Repligen Corporation has higher revenue and earnings than Check-Cap. Check-Cap is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

13.4% of Check-Cap shares are owned by institutional investors. Comparatively, 98.5% of Repligen Corporation shares are owned by institutional investors. 1.5% of Repligen Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Check-Cap and Repligen Corporation, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap 0 0 3 0 3.00
Repligen Corporation 0 2 1 0 2.33

Check-Cap currently has a consensus target price of $6.00, indicating a potential upside of 222.58%. Repligen Corporation has a consensus target price of $35.67, indicating a potential downside of 9.15%. Given Check-Cap’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Check-Cap is more favorable than Repligen Corporation.

Profitability

This table compares Check-Cap and Repligen Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Check-Cap N/A -87.96% -73.08%
Repligen Corporation 11.93% 9.57% 5.64%

Summary

Repligen Corporation beats Check-Cap on 9 of the 12 factors compared between the two stocks.

About Check-Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing. The Company’s scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. Its scanning capsule employs low-dose X-rays, which allow the system to image the interior lining of the colon even when surrounded by intestinal content. Its capsule transmits information to a receiving device worn on the patient’s body that stores the information for off-line analysis.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.